Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Opus Genetics, Inc. (Nasdaq: IRD) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other filings that document material events, financing transactions, and clinical or regulatory milestones. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, and its filings offer detailed insight into these activities.
Through its Form 8-K filings, the company reports material agreements and financings, such as securities purchase agreements for registered direct offerings of common stock and pre-funded warrants, including the use of proceeds to advance its LCA5 and BEST1 gene therapy clinical programs. These filings may also describe the terms of pre-funded warrants, closing conditions, and related legal opinions. Additional 8-Ks furnish press releases that announce financial results, cash position, and collaboration revenue, providing context on how Opus Genetics funds its research and development operations.
Regulation FD disclosures and other events reported in SEC filings frequently cover clinical and regulatory developments, including positive data from the OPGx-LCA5 Phase 1/2 trial, enrollment updates, and outcomes of FDA interactions such as Regenerative Medicine Advanced Therapy (RMAT) meetings. The company also uses 8-Ks to disclose inducement equity awards granted under its 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, these filings are paired with AI-powered summaries that help explain the key points of each document, from financing structures to trial design details. Users can review Opus Genetics’ quarterly and annual reports when available, as well as current reports and exhibits, to better understand its ophthalmic gene therapy pipeline, collaboration arrangements, and capital structure as described in its official SEC submissions.
Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic share withholding related to equity compensation. On January 18, 2026, 3,390 shares of common stock were withheld by the company at a value of $2.10 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. After this withholding, she beneficially owned 106,628 shares of Opus Genetics common stock directly. The footnote clarifies this was not an open market sale of securities but a tax-related withholding by the issuer.
Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Fin. Quality Assurance, reported a share withholding related to equity compensation. On 01/10/2026, the issuer withheld 3,950 shares of common stock at $1.93 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. This was not an open market sale of securities, but an administrative tax withholding. After this transaction, Rabourn beneficially owned 110,018 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. is highlighting its business at the 44th Annual J.P. Morgan Healthcare Conference, where management will deliver a corporate presentation on January 15, 2026 at 8:15 a.m. Pacific Time. A live webcast of the talk will be available through the company’s investor relations website, allowing investors to listen remotely. The associated January 2026 corporate presentation is provided as Exhibit 99.1 and is also posted in the “Overview” section of the company’s investor site.
Opus Genetics, Inc. director Cam Gallagher reported a new equity award and his current share holdings. On January 6, 2026, he received a grant of 67,000 restricted stock units (RSUs) of common stock at a price of $0. These RSUs vest on December 29, 2026, if he continues to provide service through that date.
After this grant, Gallagher beneficially owns 1,991,430 shares of Opus Genetics common stock directly. The filing also notes 83,000 shares held indirectly by him as custodian for a minor child under the Uniform Transfers to Minors Act, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.
Opus Genetics, Inc. furnished a current report to share a new corporate update with investors. The company submitted an 8-K that includes a press release titled “Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts,” indicating it has summarized recent achievements from 2025 and outlined important expected milestones for 2026. The information is provided under a disclosure item that is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
Opus Genetics (IRD) filed its Q3 2025 10‑Q, reporting license and collaboration revenue of $3.079 million and a net loss of $17.454 million (basic and diluted loss per share $0.25). For the first nine months of 2025, revenue was $10.331 million with a net loss of $33.068 million.
Cash and cash equivalents were $30.815 million with total assets of $36.122 million. Warrant liabilities stood at $21.325 million, reflecting the March 2025 financings. Stockholders’ equity was $5.967 million. The company stated its cash is expected to fund operations for at least the next 12 months from the financial statement issuance date.
During 2025, Opus raised capital via an underwritten offering and private placement in March, an ATM program, and a related‑party funding agreement for the MERTK program. The Series A preferred stock converted into 14,145,374 common shares on May 5, 2025. Common shares outstanding were 64,544,096 at September 30, 2025, and 68,964,208 as of November 10, 2025.
Opus Genetics, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025, and has shared these details through a press release.
The company furnished this press release as Exhibit 99.1 to a current report, allowing investors to review the full quarterly results and commentary there. The information in this report and the exhibit is treated as furnished rather than filed under the securities laws, which affects how it is incorporated into other regulatory filings.
Opus Genetics entered a securities purchase agreement for a registered direct offering, selling 3,827,751 shares of common stock and issuing pre-funded warrants for 7,177,033 shares. Shares are priced at $2.09 and the pre-funded warrants at $2.0899 (with a $0.0001 exercise price). Gross proceeds are expected to be approximately $23.0 million, with closing expected on or about November 7, 2025, subject to customary conditions.
The company plans to use net proceeds to advance its LCA5 and BEST-1 gene therapy clinical programs and for working capital and general corporate purposes. The transaction was conducted without a placement agent or underwriter, so no underwriting discounts or commissions are being paid. The pre-funded warrants are immediately exercisable and include a beneficial ownership cap of 4.99% (or 9.99% at holder election). The securities were offered under the company’s effective Form S-3 (File No. 333-276462).
Opus Genetics (IRD) filed an 8‑K announcing a $23 million registered direct offering and the successful completion of a Type B RMAT meeting with the FDA for OPGx‑LCA5, its gene therapy for LCA5‑related blindness. The FDA provided constructive feedback on Chemistry, Manufacturing and Controls and pivotal trial design and acknowledged the significant unmet medical need, noting regulatory flexibility for rare genetic diseases.
In Phase 1/2, six late‑stage participants treated with OPGx‑LCA5 experienced clinically meaningful vision improvements. The Phase 3 portion is planned as a single‑arm, 12‑month, adaptive study enrolling as few as eight participants, with a run‑in to establish each participant’s natural history as their own control. Dosing is anticipated in the second half of 2026 after validated commercial‑process supply, with topline data expected about one year later. Including expected offering proceeds, the company projects cash resources funding operations into the second half of 2027.
Opus Genetics (IRD) launched a primary offering of 3,827,751 shares of common stock and 7,177,033 pre‑funded warrants at $2.09 and $2.0899, respectively, for gross proceeds of approximately $23.0 million, before ~$0.3 million of expenses. The pre‑funded warrants are immediately exercisable at $0.0001 per share and this prospectus also covers 7,177,033 shares issuable upon their exercise. There is no underwriter or placement agent.
The company estimates net proceeds of about $22.7 million, assuming full warrant exercise, to advance its LCA5 and BEST1 gene therapy programs and for working capital and general corporate purposes. Shares outstanding were 65,002,665 as of October 31, 2025; the company states 76,007,449 would be outstanding assuming full exercise of the pre‑funded warrants.
Recent updates note constructive FDA RMAT feedback on OPGx‑LCA5 and a planned Phase 3 design, with dosing anticipated in the second half of 2026 and topline data about a year later. Including expected proceeds, management projects cash resources funding operations into the second half of 2027.